Are GLP-1 Drugs Psychiatrically Safe? One Question Remains
Millions of patients taking glucagon-like peptide-1 receptor agonists (GLP-1RAs) for type 2 diabetes and obesity face renewed clarity regarding psychiatric safety, according to a systematic review published in the journal Cureus by Quadir et al. Researchers evaluating 11 primary studies representing over 4.9 million patients found no consistent class-wide increase in neuropsychiatric risks such as … Read more